Home > Boards > US OTC > Medical - Healthcare > BioLight Life Sciences Ltd. ADR (BLGTY)

Valuation

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 127
Posts 25,940
Boards Moderated 7
Alias Born 02/07/04
160x600 placeholder
midastouch017   Thursday, 09/03/15 12:51:17 PM
Re: midastouch017 post# 32
Post # of 48 
Valuation

Quote:
Several catalysts in the pipeline have the potential to drive up shareholder value. IOPtiMate systems have yet to be fully launched in Europe. We anticipate a significant increase in system/procedure sales in 2015 and 2016 as demand grows for state-of-the-art technologies in glaucoma surgery. We are looking forward to the results from the clinical trials employing the TeaRx and EyeD technology. OphRx’s molecule, a nascent-stage product in the pipeline could be a potential source of revenue in the long term.

We believe in BioLight’s strategy of diversifying its portfolio, particularly in ophthalmology. We continue to like the story as the company continues to execute its growth strategy. We maintain our Buy rating.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences